Week 7: Metastasis and Invasion Flashcards

1
Q

Epithelial-Mesenchymal Transition (EMT)

A
  • The stage where the tumour cells break away from the primary tumour
  • Allows epithelial cells to lose connections with neighbouring cells to then break away from the primary tumour
  • The cell undergoes reprogramming
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Proteins that increase in abundance in EMT

A
  • N-cadherin
  • Vimentin
  • Fibronectin
  • Snail1 +-2
  • Twist
  • Goosecoid
  • FOXC2
  • Sox10
  • MMP-2, -3, -9
  • Integrin ab6
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Proteins that decrease in abundance in EMT

A
  • E-cadherin
  • Desmoplakin
  • Cytokeratin
  • Occludin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Proteins with increased activity in EMT

A
  • ILK
  • GSK-3B
  • Rho
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Proteins that accumulate in the nucleus

A
  • B-catenin
  • Smad-2 or -3
  • NF-kB
  • Snail
  • Slug
    -Twist
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Epithelial markers

A
  • E-cadherin
  • Claudins
  • Occludins
  • ZO-1
  • Desmoplakin
  • Cytokeratins
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Mesenchymal markers

A
  • N-cadherin
  • Fibronectin
  • Collagen 1/3
  • Snail
  • aSMA
  • Vimentin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

The ECM

A
  • The ECM not only acts as a supporting structure/scaffolding for cells, but it also acts as a cage
  • Its 3D matrices make it difficult for normal cells to move through as they only possess 2D movement, which are 2 completely different things
  • Once cancer cells become motile, they can acquire adaptations to move through the ECM or to alter it for ease of motility
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Meatrix metalloproteases (MMPs) + Tissue Inhibitors of Metalloproteases (TIMPs)

A
  • MMPs are not normally expressed in epithelial cells, but is expressed in fibroblasts, and MMPs function to degrade the ECM
  • TIMPS are a family of MMP inhibitors
  • Most MMPs can only be inhibited after they are activated but some MMPS can bind to TIMPS in their inactive forms
  • There are 4 members of TIMPs that can inhibit all MMPs
  • Cancer cells can exploit fibroblasts to degrade the ECM or possess these enzymes themselves
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Metastasising with the circulatory system

A
  • Different cancers have different prefences for their metastatic sites
  • These preferences are a result of the circulatory system
  • In some cases the cancer will settle in the organ it first passes on, but some tumour cells can circulate for hours before settling
  • Lymph vasculature is also a common route for metastasis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Challenges of surviving in the bloodstream as a cancer cell

A
  • Shear forces
  • Velocity-associated pressure
  • The presence of immune cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Different cancers also have very different behaviours/tendencies/propensities for metastasis

A
  • Examples:
    + Lung cancers are typically aggressive + spread early
    + Colon cancers generally spread late
    + Some cancers metastasis occurs late or rarely
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Metastasis by body cavity

A
  • Some cancers can spread from organ to organ within these cavities
  • Example: Peritoneal cavity contains
    + Liver
    + Stomach
    + Intestines
    + Pancreas
    + Ovaries
  • Tumours that develop in the above organs can spread to other organs without using any vasculature
  • Production of ascites by primary tumours helps to spread cancer cells to other organs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Metastatic colonosation

A
  • Metastasis can end in colonisation or cell death, most likely cell death as metastasis is a long and inefficient process for cancer cells
  • <0.02% of tumour cells entering the circulation resilt in the formation of a new tumour at a distant site
    -The rate-limiting step appears to be proper establishment + colonisaiton of new tumours at distant sites, not the dissemination to these sites
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

The metastatic niche

A
  • Once cancer cells arrive at the distant site, they are generally incapable of significant proliferation due to an absence of necessary environmental cues
  • Often these metastatic niches, ECM, secreted factors + surrounding cell types are all different than the primary site, so the tumour can remodel the environment to better suit its growth
  • Some primary tumours may secrete pre-metastatic niche factors prior to arrival to make metastasis more likely
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Treating + Preventing metastasis

A
  • Due to its complexity, there are many potential therapeutic targets
  • Many of the therapeutic targets teo date have been MMPs + components of the EMT process
  • So far there is a lot of potential targets but not a lot of success, with no current approved therapies for treating/inhibiting metastasis
17
Q

Why have the treatments failed?

A
  • Robustness + adaptability of the cancer cells, where inhibiting one signalling pathway can activate an alternative pathway
  • More than 1 MMP/protease is usually in play, so there are blocking only a few may not significantly slow down matrix degradation
  • Blocking ECM leads to a switch in movement type ie mesenchymal to ameboid movement, which doesn’t require ECM degradation
  • Usually at that point its too late to treat
18
Q

The future for metastatis therpay

A
  • Targeting cancer stem cell niche
  • Targeting pre-metastatic niche
  • Earlier diagnosis of cancer to allow the treatment before metastasis can occur
  • Combination therapies
  • Activating the immune system
  • Continued research into the molecular + cellular mechanisms regulating metastasis to identify new therapeutic targets